Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is needed to produce ergosterol, a key component of the fungal cell membrane. This inhibition causes squalene to build up and ergosterol to deplete, disrupting the membrane and leading to fungal cell death.

The exact amount of Lamisil to apply and the length of treatment are determined by the prescribing healthcare professional based on the infection type, location and severity. Patients should follow the instructions provided on the product label or by their clinician.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider before using Lamisil.

To request Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil (terbinafine) belongs to the allylamine class, which generally provides rapid fungicidal activity and a short treatment course compared with many azole or polyene creams. It is often preferred for dermatophyte infections because of its high cure rates and low systemic absorption when used topically.

Lamisil should be stored at room temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the tube tightly closed helps maintain product stability.

The cream or solution is applied to clean, dry skin in a thin layer, usually twice daily, covering the affected area and a small margin of surrounding healthy skin. Hands should be washed after application, and the treated area should not be covered with airtight dressings unless directed by a clinician.

While rare, serious adverse reactions can include severe allergic responses such as contact dermatitis, angioedema, or Stevens‑Johnson syndrome. If any signs of a serious skin reaction or systemic symptoms appear, the product should be discontinued and medical attention sought immediately.

Individuals with known hypersensitivity to terbinafine or any component of the formulation should avoid using Lamisil. It should also not be applied to broken skin, mucous membranes, or the eyes, and patients with severe liver disease should consult a physician before use.